CCG-203971

CCG-203971 is a second-generation Rho/MRTF/SRF pathway inhibitor. CCG-203971 potently targets RhoA/C-activated SRE-luciferase (IC50 =6.4 μM). CCG-203971 inhibits PC-3 cell migration with an IC50 of 4.2 μM. Potential anti-metastasis Agent.


Cat. No.: EX-A1813	Purity: >98%

	Chemical structure of CCG-203971

For research only, Do not use for Human!

Size	Unit Price (US$)	Stock
500mg	650	In-stock
1g	900	In-stock
2g	1600	In-stock
5g	3500	In-stock
10g	5285	In-stock

Send PO to E-mail:[email protected]; or Fax:+86 020 81619670

Discount Request


CAS No.	1443437-74-8
Purity	>98%
Formula	C23H21ClN2O3
Mol Weight	408.877
State	solid powder
Solubility	Soluble in DMSO
Shelf Life	>2 years if stored properly
Storage	Powder -20℃ 2 years; In solvent -20℃ 1 month;
Shipping	Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Reference:	[1]. Bell JL, et al. Optimization of novel nipecotic bis(amide) inhibitors of the Rho/MKL1/SRF transcriptional pathway as potential anti-metastasis agents. Bioorg Med Chem Lett. 2013 Jul 1;23(13):3826-32. [2]. Johnson LA, et al. Novel Rho/MRTF/SRF inhibitors block matrix-stiffness and TGF-β-induced fibrogenesis in human colonic myofibroblasts. Inflamm Bowel Dis. 2014 Jan;20(1):154-65.
CoA	CoA of CCG-203971

Smiles:	ClC1=CC=C(NC(=O)C2CCCN(C2)C(=O)C2=CC=CC(=C2)C2=CC=CO2)C=C1


		Search